RSS   Newsletter   Contact   Advertise with us

Swiss Competition Commission investigates pharma suppliers

Christian Fernsby ▼ | February 24, 2020
The Swiss Competition Commission (COMCO) has opened an investigation against several manufacturers and distributors of active pharmaceutical ingredients.
Scopolamine Butylbromide
Business in Switzerland   Scopolamine Butylbromide
COMCO has conducted several dawn raids.

Topics: Swiss competition pharma

COMCO suspects that manufacturers and distributers of the active pharmaceutical ingredient Scopolamine Butylbromide have concluded unlawful price and market sharing agreements.

There are reasonable grounds to suspect that the undertakings have kept the prices of this pharmaceutical ingredient high and that they have allocated markets.

The investigation shall examine whether there are indeed unlawful restrictions of competition.

This pharmaceutical ingredient is used for the production of drugs against spasmodic stomach pains, renal colic and bladder spasms.

The manufacturers and distributors of Scopolamine Butylbromide resell this pharmaceutical ingredient to drug manufacturers.